Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
Pluristem Therapeutics (NASDAQ:PLUR) Inc. shares have reached a 52-week low, dipping to $4.00, as the biotechnology firm faces a challenging market environment. According to InvestingPro data, the company’s high volatility (Beta 1.76) and market capitalization of $29.25M reflect its current challenges, though its strong current ratio of 5.04 indicates solid short-term liquidity. This latest price level reflects a significant downturn from the stock’s performance over the past year, with Pluristem experiencing a 1-year change of -16.4%. Investors are closely monitoring the company’s progress and strategic initiatives as it navigates through the headwinds that have pressured the stock to its current low point. Despite these challenges, InvestingPro analysis reveals impressive revenue growth of 89.92% and projects positive net income growth ahead. The market will be looking for signs of recovery and positive momentum in the coming quarters to assess the potential for Pluristem’s rebound from this 52-week low watermark. InvestingPro subscribers have access to 8 additional key insights about PLUR’s financial health and growth prospects.
In other recent news, Pluri Inc. has entered into an exclusive agreement with Ukrainian biobank Hemafund to advance its PLX-R18 cell therapy for Hematopoietic Acute Radiation Syndrome. This collaboration aims to stockpile 12,000 doses, potentially generating over $100 million if successful. The partnership, which responds to recent regional escalations, will last for an initial three years with an option to extend. Additionally, Pluri Inc. has been granted an extension by Nasdaq to meet the exchange’s continued listing requirements, with a deadline set for May 24, 2025. The company had received a deficiency notice for failing to maintain the minimum required stockholders’ equity. Pluri’s management is committed to taking necessary measures to regain compliance. Meanwhile, the company has announced its 2025 Annual Meeting of Shareholders, scheduled for May 14, 2025, in Haifa, Israel. This meeting marks a shift of more than 30 days from the previous year’s meeting date.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.